69results about "Enzymology" patented technology

Provided herein are methods for capturing an analyte from a first region of interest of a biological sample on a substrate, where the biological sample comprises the first region of interest and a second region, and where the method includes contacting the second region with a sealant in order to create a hydrophobic seal thereby preventing an interaction between an analyte from the second region with a capture domain of a capture probe.

A reagent kit, staining method, and application for combining dual immunohistochemistry with elastin fiber staining. The reagent kit includes a combination of primary antibodies, consisting of anti-CK7 and anti-CD34 monoclonal antibodies from different species, such as rabbit anti-human CK7 monoclonal antibody and mouse anti-human CD34 monoclonal antibody. By selecting CK7 and CD34 as the primary antibody combination, the growth pattern of tumor epithelium can be accurately indicated, and the proliferation and thickening of alveolar septal fibrous tissue caused by tumors can be clearly revealed, as opposed to structural changes of alveoli induced by other factors. Combined with independent Victoria blue staining, the elastin fibers of the walls of arteries and veins, as well as the pleura of the lungs, can be clearly visualized, aiding in the assessment of the integrity of elastin fibers on the lung surface and in determining the extent of tumor infiltration.

The invention discloses a skeletal muscle repair method and system based on muscle satellite cell regulation and control. The method comprises the following steps: performing proliferation and differentiation correlation analysis on satellite cell steady state data and aerobic exercise intensity data to establish a proliferation regulation and control map; determining a collaborative repair time window according to the atlas, extracting difference response deviation correction parameters to form an activity correction factor, and performing repair intensity correction on the collaborative repair time window to generate a self-adaptive repair window; carrying out exercise prescription adaptation on the self-adaptive repair window, identifying a satellite cell activation regulation and control channel, obtaining activation delay time through activation efficiency mapping, and delimiting a response level according to the activation delay time to generate layered repair configuration; activation delay evaluation is conducted on layered repair configuration to determine a preferred activation mode, dynamic activation characteristics are extracted based on optimal activation time window data to form an intervention execution sequence, a skeletal muscle repair execution instruction is output in combination with an exercise prescription parameter table, and dynamic collaborative adaptation of satellite cell repair state monitoring and training scheme parameters is achieved.

The disclosure relates to methods for treating cancer or selecting subjects for cancer treatment using low PD-L1 expression as a patient biomarker prior to treatment.

Disclosed herein are biomarkers that correlate with responses to an anti-ILT4 and anti-PD-1 combination therapy. A biomarker that can differentiate responders from non-responders to this combination therapy can potentially be used to select human subjects who have a higher probability to benefit from such a combination therapy. In one embodiment, a combined positive score (CPS) for PD-L1 expression in a tumor sample from a human subject is used as a biomarker to differentiate a responder from a non-responder to an anti-ILT4 and anti-PD-1 combination therapy. In another embodiment, a T-cell–inflamed gene expression profile (TcellinfGEP) score is used as a biomarker to differentiate a responder from a non-responder to an anti-ILT4 and anti-PD-1 combination therapy.

In alternative embodiments, there is provided an immunohistochemistry (IHC) method for determining and reproducibly scoring the nuclear expression level of protein Ki-67 (also known as MKI67) in tissue samples.In alternative embodiments, there is provided a method for diagnosing, treating, or improving cancer or tumor, or assessing the risk of its recurrence, using the IHC method provided herein.In alternative embodiments, there is provided a kit, which includes components and instructions for carrying out the method provided herein.

Provided are an antibody and an antigen-binding fragment that specifically bind to Nectin-4, and a test kit containing the antibody or the antigen-binding fragment. Also provided are a nucleic acid encoding the antibody, a host cell containing the nucleic acid, and a method for preparing the antibody. Also provided are uses of the antibody specifically binding to Nectin-4 in diagnosis and prognosis.

Disclosed are methods of treating of a subject having cancer comprising applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more cancer cells, wherein the subject has an isocitrate dehydrogenase mutation (IDHmut). Disclosed are methods of treating a subject comprising identifying a subject with an IDHmut; and applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more cancer cells.

The present disclosure relates to an engineered M13 bacteriophage displaying amyloidogenic peptide motifs from amyloid beta 42 (Aβ42) at its surface. The present disclosure further relates to the use of the disclosed engineered M13 bacteriophage for detecting early species of Aβ, namely oligomeric and fibrillar Aβ, and preventing its aggregation promoting the inhibition of the progression of Alzheimer's disease and thus contributing to the treatment of this neurodegenerative disorder.

The invention relates to the technical field of immune globulin, in particular to an anti-gastrin antibody and a hybridoma cell strain and application thereof. The invention provides an anti-gastrin antibody, and also provides a hybridoma cell strain OTI3D11, and the preservation number of the hybridoma cell strain is CGMCC (China General Microbiological Culture Collection Center) No.46359. The invention also provides an anti-gastrin antibody and a hybridoma cell strain OTI3D11. According to the present invention, the hybridoma cell strain OTI3D11 can stably secrete the anti-gastrin monoclonal antibody, and can specifically bind to the Gastrin protein (especially G-17), such that the immunodetection of the hybridoma cell strain OTI3D11 has specificity and sensitivity, and the hybridoma cell strain OTI3D11 can be suitable for the labeling of the Gastrin protein in tissue cells.

A method and apparatus for labeling a tissue section is provided. In certain aspects, the methods comprise labeling a tissue sample via a plurality of immunohistochemistry (IHC) assays for detection of markers for characterization of a cancer origin in an individual having a cancer of unknown primary (CUP). The disclosed IHC assays employ chromogen-based detection methods for improved sample efficiency and visualization of biomarkers. Further disclosed is an apparatus for carrying out the disclosed methods.

This invention discloses an antibody (YWHG-4) against HLA-G isoform molecules HLA-G1, HLA-G4, and HLA-G5, and its uses. The antibody (YWHG-4) is produced from a hybridoma with accession number CCTCC NO:2021204, using the antigenic peptide (RGYYNQSEASSHTLQWMIGC) of amino acid position 106-126 of the HLA-G molecule heavy chain as the immunogen. This invention provides the nucleotide encoding the YWHG-4 antibody and its encoding amino acid sequence. Furthermore, this invention provides the uses of the YWHG-4 antibody for the detection of HLA-G isoform molecules HLA-G1, HLA-G4, and HLA-G5 using Western blotting, immunohistochemistry, ELISA, and flow cytometry.

The present invention provides anti-carcinoembryonic antigen (CEA) antibodies for use in detecting CEA, treating disorders associated with CEA expression, diagnosing cancers characterized by aberrant CEA expression, and predicting the efficacy of cancer chemotherapy. Anti-CEA antibodies, antibody fragments, monoclonal antibodies, antibody conjugates, compositions comprising the described antibodies, and methods of their use are provided.

Provided are methods for treating cancer by converting tumor-resident macrophages to a hybrid M1 / M2 macrophage phenotype, which has attributes that are advantageous for cancer therapy. Hybrid markers (lower than M2 and higher than M1) include SPP1, CD209, and CD206, and inducible markers include MERTK, C1QC, IFNa, IFNb, CXCL10, 4-1BBL, and MYC. The method includes administering a therapeutic agent that achieves the phenotype conversion. The therapeutic agent, such as a delivery vehicle that includes an immunostimulatory bacterium with genomic modifications, is designed to inhibit type I IFN by not inducing or resulting in sufficient TLR2, TLR4, TLR5 responses. The therapeutic agent also encodes a payload that encodes an immunostimulatory protein, e.g., a cytokine, and a modified intracytoplasmic DNA / RNA sensor that constitutively induces type I IFN, such as a modified STING protein. The combination of the properties of the payload immunostimulatory protein and the therapeutic delivery vehicle, when administered, results in macrophages with a hybrid phenotype. The therapeutic agent is administered to a subject identified as having a tumor that contains proliferating M2 macrophages.

The present invention relates to methods and systems for detecting one or more analytes in a sample and / or for classifying a sample. In particular, the present invention relates to methods and systems which can be used to detect the analytes in real time and which rely on flowing through a microfluidic device one or more types of sensor molecule each comprising a domain that binds one or more analytes, a chemiluminescent donor domain and an acceptor domain, wherein the separation and relative orientation of the chemiluminescent donor domain and the acceptor domain, in the presence and / or absence of analyte is within ± 50% of the Forster distance.

The invention provides a marker, a kit containing the marker, application of the marker and a use method of the marker. The marker comprises at least one selected from the group consisting of MUC1, MUC5AC, and Claudin18.2. The invention also relates to a method for preparing the marker. The marker and the kit containing the marker can be used for predicting prognosis of the intrahepatic cholangiocarcinoma, predicting the curative effect of targeted therapy and postoperative adjuvant therapy on the intrahepatic cholangiocarcinoma based on tumor expression states, and performing classified prediction on a big bile duct type and a small bile duct type of the intrahepatic cholangiocarcinoma. The disclosure also provides a method of cancer prognosis comprising detecting the expression of the marker and predicting the degree of benefit from post-operative adjuvant therapy in a subject, and / or the prognosis of cancer, particularly intrahepatic cholangiocarcinoma, in a subject. The present disclosure provides universal markers that can be used to predict the efficacy of postoperative adjuvant therapy, such as postoperative adjuvant chemotherapy, on intrahepatic cholangiocarcinoma.

The application discloses an antibody (YHWG-1) against HLA-G molecules and application, the antibody (YHWG-1) is produced by hybridoma with the preservation number of CCTCC NO:202120, using all currently known 7 HLA-G isomer molecules (HLA-G1, HLA-G2, HLA-G3, HLA-G4, HLA-G5, HLA-G6 and HLA-G7) shared, the antigen peptide (QTDRMNLQTLRGYYNQSEAS) of the 72~91 amino acid sequence in the HLA-G molecule heavy chain alpha 1 domain is immunogen.The application provides nucleotide and the amino acid sequence coded by the YHWG-1 antibody of the application, and the application also provides the application of the YHWG-1 antibody for HLA-G isomer molecule immunohistochemical, immunoblotting and flow cytometry detection.

Disclosed are methods of treating of a subject having cancer comprising applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more cancer cells, wherein the subject has an isocitrate dehydrogenase mutation (IDHmut). Disclosed are methods of treating a subject comprising identifying a subject with an IDHmut; and applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more cancer cells.

The invention provides an anti-human CXCL13 rabbit monoclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of immune globulin, the anti-human CXCL13 rabbit monoclonal antibody can be specifically combined with CXCL13 protein, the specificity and sensitivity of immunodetection are remarkably improved, the anti-human CXCL13 rabbit monoclonal antibody is suitable for preparing an immunohistochemical detection kit, and the anti-human CXCL13 rabbit monoclonal antibody can be used for preparing immunohistochemical detection products. CXCL13 protein expression can be accurately detected, and a reliable tool is provided for diagnosis of diseases such as vascular immune maternal T cell lymphoma and peripheral T cell lymphoma.

Aspects of the present disclosure are directed to survivin-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such survivin-targeting polypeptides and cells comprising such nucleic acids. Described are methods for detection, diagnosis, and treatment of cancer using survivin-targeting polypeptides.

Disclosed herein is a kit to detect and determine post-synaptic density protein-95 (PSD-95) levels in subjects with peripheral neuropathy. Also disclosed herein, is a method of treating or preventing neuropathy in a subject. The method comprises detecting PSD-95 levels in a sample from the subject, using the kit disclosed herein and when the PSD-95 level differs from a control, the subject is treated for neuropathy.

Disclosed in the present invention are a monoclonal antibody (YWHG-4) against HLA-G isoforms (HLA-G1, HLA-G4, HLA-G5) and use thereof. The antibody (YWHG-4) is produced by the hybridoma deposited under CCTCC NO: 2021204, and an antigenic peptide (RGYYNQSEASSHTLQWMIGC) of amino acid sequences at positions 106-126 of a heavy chain of HLA-G molecules is used as an immunogen. Provided in the present invention are a nucleotide encoding the YWHG-4 antibody of the present invention and an encoded amino acid sequence thereof. Further provided in the present invention is use of the YWHG-4 antibody in the detection of the HLA-G isoforms (HLA-G1, HLA-G4, HLA-G5) by means of immunoblotting, immunohistochemistry, ELISA and flow cytometry.

The present invention provides: a production method for a conjunctival epithelial cell mass that is characterized by including (1) a step for inducing differentiation of conjunctival epithelial stem / precursor cells from pluripotent stem cells, (2) a step for collecting cells that express a conjunctival epithelium marker selected from the group that consists of BST2, SLC2A3, AGR2, TMEM54, OLR1, TRIM29, and CITED2 from the resulting conjunctival epithelial stem / precursor cells, and (3) a step for culturing and maturing the cells that express the conjunctival epithelial marker; a detection method for conjunctival epithelial cells that is characterized by detecting the cells of an eye surface epithelial cell mass that express a conjunctival epithelial cell marker selected from the group that consists of BST2, SLC2A3, AGR2, TMEM54, OLR1, TRIM29, and CITED2; and a method for improving the purity of conjunctival epithelial cells in an eye surface epithelial cell mass that is characterized by collecting cells that express a conjunctival epithelial marker selected from the group that consists of BST2, SLC2A3, AGR2, TMEM54, OLR1, TRIM29, and CITED2. The present invention can be used to produce conjunctival epithelial cell masses and to detect and improve the purity of conjunctival epithelial cells.

The invention provides methods and compositions for accurate identification and determination of Parkinson's disease ante-mortem tissue samples. The determination of Parkinson's disease is based on the binding of localized phosphorylated alpha-synuclein with the nerve feature. The methods disclosed in the invention may be used on myriad tissue types and could be manual or automated.

A method for pre-treatment identification of cancer patients that respond to anti-CLEVER-1 therapy comprising an administration of an agent capable of binding to CLEVER-1 in a patient. In the method. the presence of PD-L1 expressing cells and CLEVER-1 expressing cells is detected in a tumor sample obtained from a cancer patient. by immunohistochemistry staining by a PD-L1 specific antibody and a mouse monoclonal lgG2a kappa STAB-1 antibody (clone 4G9), and then a percentage of PD-L1 expressing cells from the total amount of viable cells present in the stained sample, and a percentage of intra-tumoral CLEVER-1 expressing cells from the total amount of viable intra-tumoral cells present in the stained sample. is calculated. A tumor sample which shows low percentage of PD-L1 expressing cells or not comprising PD-L1 expressing cells together with substantial percentage of CLEVER-1 expressing intra-tumoral cells is an indication that the cancer patient is responsive to the anti-CLEVER-1 therapy.

The invention relates to an in-vitro analysis method for identifying correlation between GLS1 activity and left ventricular hypertrophy in chronic kidney diseases, which comprises the following steps: firstly, constructing a chronic kidney disease mouse model, carrying out heart space metabonomics detection, carrying out heart tissue enzyme activity detection and heart immunohistochemical analysis on the frozen heart of the mouse, and determining the correlation between GLS1 activity and left ventricular hypertrophy. Normal neonatal mouse myocardial primary cells are extracted and subjected to real-time quantitative PCR detection, protein determination and protease activity detection respectively, then intervened cells are collected with the kit, mitochondrial function determination, metabolic flux determination, ammonia production determination and acetylation determination are performed, and finally clinical observation experiments are performed. The correlation analysis of the left ventricular hypertrophy index of a chronic kidney disease patient and the enzyme activity of kidney-type glutaminase is carried out, the new application of the CB839 targeting GLS1 in resisting the left ventricular hypertrophy of the chronic kidney disease and delaying the progress of the IV-type kidney-heart syndrome is formulated according to the analysis result, and the application has the advantages of developing the new application of drugs and being good in effect of relieving the left ventricular hypertrophy.

Methods and reagents suitable for in vitro diagnostic assay comprising a qualitative immunohistochemical assay using anti-Globo H antibodies and / or binding fragments thereof are provided. The method comprises the detection of Globo-H expression levels in formalin-fixed, paraffin-embedded (FFPE) cancer tissue using a visualization system. The Globo-H expression can be determined by using tumor scoring showing partial or complete staining at any intensity.

The disclosure relates to a sample image capturing system, including: a sample holding apparatus configured to hold a sample slide on which a sample film is applied; an imaging apparatus configured to capture the sample on the sample slide; a sample appearance image obtaining apparatus configured to obtain a sample appearance image, where the sample appearance image includes at least an appearance image of the sample film; and a controller configured to: obtain the sample appearance image, identify an appearance characteristic of the sample film based on the sample appearance image, determine a capturing parameter based on the appearance characteristic, and control the imaging apparatus to capture, with the capturing parameter, sample components on the sample slide. The disclosure further relates to a sample image capturing method and a computer-readable storage medium. The disclosure can use a characteristic of the appearance image to achieve accurate capturing of sample images.